Navigation Links
Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease
Date:4/10/2008

NEW YORK, April 10 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), announced today that it has obtained a Notice of Allowance and completed the grant requirements to obtain a European patent relating to the Company's ANTISENILIN(R) antibodies and products being developed by the Company for the treatment of Alzheimer's disease. Grant of the European patent is expected in several weeks. Other patents related to the ANTISENILIN(R) antibodies have been granted in Japan, China and elsewhere. Patent applications are pending in the United States. Intellect Neurosciences is the exclusive assignee of the ANTISENILIN(R) patents, which are based on the invention of Dr. Daniel Chain, the Company's Chairman and CEO.

Dr. Chain commented: "The use of ANTISENILIN(R) monoclonal antibodies that specifically target the toxic forms of beta amyloid is at the forefront of the battle against Alzheimer's disease. In addition to the Company's products in development, our invention has been applied to promising drug candidates in clinical development by major pharmaceutical companies."

"Intellect's ANTISENILIN(R) antibody technology incorporates an important safety feature ("free-end specificity"), meaning that antibodies developed using the technology are designed to specifically block the neurotoxicity of beta amyloid, which accumulates in the brains of Alzheimer's patients. The blocking of the neurotoxicity is achieved by promoting clearance of beta amyloid away from sites of damage while minimizing the potential for adverse effects," explained Professor Donald Price, Professor of Pathology, Neurology and Neuroscience and Founding Director of the Alzheimer's Disease Research Center at The Johns Hopkins School of Medicine and a member of Intellect's Scientific Advisory Board. Professor Price added: "Dr. Chain's idea of using antibodies in this way to reduce amyloid toxicity in the brain has gained considerable momentum over the past
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
4. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
5. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
6. Amarin Secures Global Intellectual Property Rights for Lipid Programs
7. ActivBiotics Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
8. Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
9. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
10. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
11. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013 Pacific Biomarkers and ... solutions for developers of biosimilars at the 2013 ... Sheraton San Diego Hotel and Marina ... will have the opportunity to speak with company representatives ... Paths That Cross" on May 21 from 1-2 p.m. ...
(Date:5/20/2013)... 20, 2013 Cempra, Inc. (Nasdaq: CEMP), ... antibiotics to meet critical medical needs in the ... presented data at the American Thoracic Society International ... demonstrating the antibacterial and enhanced immunomodulatory activity ... 2 clinical trial in outpatients with community acquired ...
(Date:5/20/2013)... Pittsburgh, PA (PRWEB) May 20, 2013 ... the Allegheny General Hospital (AGH) Cardiovascular Institute ... of coronary artery disease (CAD) over the ... procedures such as balloon angioplasty and coronary artery stent ... will once again play a prominent role in the ...
(Date:5/20/2013)... May 20, 2013 On 25-28 July, ... – in Paris - the beautiful city of lights. ... "Personalized Medicine is revolutionizing the medical world. Understanding and ... is the hallmark of this transformation. Much of the ... from the epidemiologic studies of large cohorts that do ...
Breaking Biology Technology:Pacific Biomarkers and Clinigene International To Announce Laboratory Solutions for Developers of Biosimilars at 2013 AAPS/ National Biotechnology Conference 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 3Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 4The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris 2
... (Nasdaq:,INSM), today announced that it has been awarded ... (MDA). The grant is expected to cover a,substantial ... 24-week,Phase 3 enabling trial in patients with Myotonic ... biopharmaceutical company with extensive,expertise in biologics and orphan ...
... Filed With the FDA for the Fourth Genmab Antibody ... the Company,s Collaboration with Roche., COPENHAGEN, December 12 ... New Drug application (IND) for a,Genmab antibody developed under ... FDA by Roche. Genentech and Roche are collaborating on,development ...
... Toronto Stock Exchange Symbol: MS, EDMONTON, Dec. ... leading developer in the treatment of multiple sclerosis ... Board (DSMB) has,reviewed data from the Company,s on-going ... for the treatment of secondary progressive MS and,recommended ...
Cached Biology Technology:Insmed Awarded $2.1 Million by Muscular Dystrophy Association 2Insmed Awarded $2.1 Million by Muscular Dystrophy Association 3Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 2Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 3BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2
(Date:5/17/2013)... for Experimental Biology (FASEB) released a new analysis ... highlighting the devastating impact of sequestration on the nation,s ... a May 15th Senate Appropriations Committee hearing featuring NIH ... $1.6 billion cut the agency sustained in FY 2013 ... the scientific community." , According to data from ...
(Date:5/16/2013)... Bethesda, MD FASEB MARC (Maximizing Access to ... recipients for The Society for Developmental Biology (SDB) ... 16-20, 2013. These awards are meant to promote ... underrepresented groups into the mainstream of the basic ... young scientists at the SDB 2013 Annual Meeting. ...
(Date:5/16/2013)... Injectable nanoparticles developed at MIT may someday eliminate ... to constantly monitor their blood-sugar levels and inject ... to sense glucose levels in the body and ... thereby replacing the function of pancreatic islet cells, ... diabetes. Ultimately, this type of system could ensure ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3
... post doctoral fellow Virginie Mieulet, in the Faculty of Medicine ... is so vital in fighting infection. , They have discovered ... body know that it,s being attacked by an infection. , ... could have implications for the millions of people in third ...
... Trypanosomes are parasites responsible for many human and ... parasites cause, African sleeping sickness, results from the bite ... at risk in 36 sub-Saharan countries. The recent 1998-2001 ... of Congo and Uganda killed tens of thousands of ...
... A team led by Massachusetts General Hospital (MGH) scientists ... accurately isolating neutrophils the most abundant type of ... accomplishment that could provide information essential to better understanding ... system, described in a Nature Medicine paper ...
Cached Biology News:New research shows how disease-causing parasite gets around human innate immunity 2New research shows how disease-causing parasite gets around human innate immunity 3New research shows how disease-causing parasite gets around human innate immunity 4Microfluidic device allows collection, analysis of hard-to-handle immune cells 2
... This immunoaffinity purified antibody detects an ... molecular mass of ErbB-2 phosphorylated at tyrosine ... product has been cross adsorbed against the ... detect the non-phosphorylated form of the protein. ...
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
... Synthetic peptide corresponding ... Antigen Family: ... Antigen Subfamily: not ... Recommended Storage: Long ...
Anti-DNA Polymerase a, Human Description: 50 l Research Focus: cancer & cell proliferation Storage: 4C Shipping Temperature: 4C...
Biology Products: